TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
Brief Summary: The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.


Options:
A: Arm Label: 12m DAPT Study Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo & Aspirin | Arm Label: 30m DAPT Study Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin | Intervention Type: DRUG; Name: Placebo & Aspirin; Assigned to Arm(s): 12m DAPT Study Arm | Intervention Type: DRUG; Name: Clopidogrel & Aspirin, Prasugrel & Aspirin; Assigned to Arm(s): 30m DAPT Study Arm
B: Arm Label: Short triple; Type: EXPERIMENTAL; Interventions: Drug: aspirin, Drug: clopidogrel, Drug: oral anticoagulation | Arm Label: Long triple; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Drug: oral anticoagulation | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Long triple, Short triple | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Long triple, Short triple | Intervention Type: DRUG; Name: oral anticoagulation; Assigned to Arm(s): Long triple, Short triple
C: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
D: Arm Label: Warfarin/placebo edoxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin tablets, Drug: placebo edoxaban | Arm Label: high dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (high dose regimen-60mg), Drug: placebo warfarin | Arm Label: low dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (low dose regimen-30mg), Drug: placebo warfarin | Intervention Type: DRUG; Name: warfarin tablets; Assigned to Arm(s): Warfarin/placebo edoxaban | Intervention Type: DRUG; Name: Edoxaban tablets (high dose regimen-60mg); Assigned to Arm(s): high dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: Edoxaban tablets (low dose regimen-30mg); Assigned to Arm(s): low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo warfarin; Assigned to Arm(s): high dose edoxaban/placebo warfarin, low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo edoxaban; Assigned to Arm(s): Warfarin/placebo edoxaban

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
Brief Summary: The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.


Options:
A: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA
B: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
C: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel, Drug: Commercially-available Aspirin | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel, Drug: Commercially-available Aspirin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Commercially-available Aspirin; Assigned to Arm(s): Clopidogrel, Prasugrel
D: Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
Brief Summary: The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.


Options:
A: Intervention Type: DRUG; Name: clopidogrel (SR25990); Assigned to Arm(s): N/A
B: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin monotherapy | Arm Label: Aspirin,Clopidogrel; Type: EXPERIMENTAL; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin monotherapy; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel
C: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
D: Arm Label: Cangrelor; Type: EXPERIMENTAL; Interventions: Drug: Cangrelor (P2Y12 inhibitor), Drug: clopidogrel (oral P2Y12 inhibitor), Drug: Placebo capsules - as soon as possible after randomization | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: clopidogrel (oral P2Y12 inhibitor), Drug: Placebo bolus & placebo infusion, Drug: Placebo capsules - end of infusion | Intervention Type: DRUG; Name: Cangrelor (P2Y12 inhibitor); Assigned to Arm(s): Cangrelor | Intervention Type: DRUG; Name: clopidogrel (oral P2Y12 inhibitor); Assigned to Arm(s): Cangrelor, Clopidogrel | Intervention Type: DRUG; Name: Placebo bolus & placebo infusion; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Placebo capsules - end of infusion; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Placebo capsules - as soon as possible after randomization; Assigned to Arm(s): Cangrelor

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
Brief Summary: The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.


Options:
A: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheterization immediate PCI | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: delayed PCI | Intervention Type: PROCEDURE; Name: Catheterization immediate PCI; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: delayed PCI; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: systematic coronary intervention | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: coronary intervention only for cases refractory to medical therapy | Intervention Type: OTHER; Name: systematic coronary intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: coronary intervention only for cases refractory to medical therapy; Assigned to Arm(s): 2
D: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
Brief Summary: The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.


Options:
A: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
D: Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: (LMW) Heparin + Vitamin K Antagonist | Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: (LMW) Heparin + Vitamin K Antagonist; Assigned to Arm(s): Arm 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Impairment in the ICU: Evaluation and Outcomes
Brief Summary: The purpose of this study is to determine the impact of a new RN/RRT (Registered Nurse/Registered Respiratory Therapist) directed 2-step protocol to wean patients off of a ventilator. This protocol involves daily attempts to halt sedation (spontaneous awakening trials) combined with daily assessments of patients while they are breathing on their own (spontaneous breathing trials).


Options:
A: Intervention Type: PROCEDURE; Name: Sedation management protocol; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Sedation management strategy; Assigned to Arm(s): N/A
C: Arm Label: PS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized Sedation | Arm Label: PS + DI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized sedation, with daily interruption | Intervention Type: PROCEDURE; Name: Protocolized Sedation; Assigned to Arm(s): PS | Intervention Type: PROCEDURE; Name: Protocolized sedation, with daily interruption; Assigned to Arm(s): PS + DI
D: Intervention Type: PROCEDURE; Name: SAT: Spontaneous Awakening Trial; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: SBT: Spontaneous Breathing Trial; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Impairment in the ICU: Evaluation and Outcomes
Brief Summary: The purpose of this study is to determine the impact of a new RN/RRT (Registered Nurse/Registered Respiratory Therapist) directed 2-step protocol to wean patients off of a ventilator. This protocol involves daily attempts to halt sedation (spontaneous awakening trials) combined with daily assessments of patients while they are breathing on their own (spontaneous breathing trials).


Options:
A: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention
B: Intervention Type: PROCEDURE; Name: SAT: Spontaneous Awakening Trial; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: SBT: Spontaneous Breathing Trial; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): N/A
D: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Impairment in the ICU: Evaluation and Outcomes
Brief Summary: The purpose of this study is to determine the impact of a new RN/RRT (Registered Nurse/Registered Respiratory Therapist) directed 2-step protocol to wean patients off of a ventilator. This protocol involves daily attempts to halt sedation (spontaneous awakening trials) combined with daily assessments of patients while they are breathing on their own (spontaneous breathing trials).


Options:
A: Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine
B: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam
C: Intervention Type: PROCEDURE; Name: SAT: Spontaneous Awakening Trial; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: SBT: Spontaneous Breathing Trial; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MOTOR: Maternal Oral Therapy to Reduce Obstetric Risk
Brief Summary: The purpose of this study is to determine whether maternal periodontal therapy (tooth cleaning) decreases the rate of preterm deliveries at \<37 weeks gestation and to determine the effects of maternal periodontal therapy on the birth weight of infants born less than 37 weeks gestation.


Options:
A: Arm Label: Periodontal Treatment; Type: EXPERIMENTAL; Interventions: Other: multi-center, randomized, controled periodontal therapy | Intervention Type: OTHER; Name: multi-center, randomized, controled periodontal therapy; Assigned to Arm(s): Periodontal Treatment
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Scaling and root planing | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Scaling and root planing | Intervention Type: PROCEDURE; Name: Scaling and root planing; Assigned to Arm(s): 1, 2
C: Arm Label: Scaling and root planing; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Periodontal scaling and root planing, Procedure: Scaling and root planing | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Periodontal scaling and root planing; Assigned to Arm(s): Scaling and root planing | Intervention Type: PROCEDURE; Name: Scaling and root planing; Assigned to Arm(s): Scaling and root planing
D: Intervention Type: PROCEDURE; Name: Treatment of periodontal disease; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VITATOPS - A Study of VITAmins TO Prevent Stroke
Brief Summary: The VITATOPS study is a multi-center, randomized, double blind, placebo-controlled secondary stroke prevention trial to determine whether the addition of vitamin supplements (B12 500 ug, B6 25 mg, Folate 2 mg) to best medical/surgical management (including modification of risk factors) will reduce the combined incidence of recurrent vascular events (stroke, myocardial infarction) and vascular death in patients with recent stroke or transient ischemic attack (TIA). All patients presenting to one of the participating neurologists or general physicians within seven months of stroke (ischemic or hemorrhagic) or TIA (eye or brain) are eligible for this trial. Eligible patients will be randomized in a double-blind fashion to receive multi-vitamins or placebo, 1 tablet daily. The primary outcome event is the composite event "stroke, myocardial infarction, or death from any vascular cause", whichever occurs first. Our target is to recruit a total of 8,000 patients over the next two years with a median follow-up of 2.5 years. Recruitment to the trial began in November 1998 and is planned to continue until December 2005. We aim to complete final follow-up by the end of 2006. However, the Steering Committee will be flexible in dictating the need for ongoing recruitment and continuing follow-up, depending on the overall rate of the primary outcome event in the entire cohort at each interim analysis.


Options:
A: Arm Label: Melatonin (N-acetyl-5-methoxytryptamine); Type: ACTIVE_COMPARATOR; Interventions: Drug: Melatonin (N-acetyl-5-methoxytryptamine) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Melatonin (N-acetyl-5-methoxytryptamine); Assigned to Arm(s): Melatonin (N-acetyl-5-methoxytryptamine) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: BA-LVR; Type: EXPERIMENTAL; Interventions: Behavioral: BA-LVR | Arm Label: ST-LVR; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: ST-LVR | Intervention Type: BEHAVIORAL; Name: BA-LVR; Assigned to Arm(s): BA-LVR | Intervention Type: BEHAVIORAL; Name: ST-LVR; Assigned to Arm(s): ST-LVR
C: Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet
D: Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VITATOPS - A Study of VITAmins TO Prevent Stroke
Brief Summary: The VITATOPS study is a multi-center, randomized, double blind, placebo-controlled secondary stroke prevention trial to determine whether the addition of vitamin supplements (B12 500 ug, B6 25 mg, Folate 2 mg) to best medical/surgical management (including modification of risk factors) will reduce the combined incidence of recurrent vascular events (stroke, myocardial infarction) and vascular death in patients with recent stroke or transient ischemic attack (TIA). All patients presenting to one of the participating neurologists or general physicians within seven months of stroke (ischemic or hemorrhagic) or TIA (eye or brain) are eligible for this trial. Eligible patients will be randomized in a double-blind fashion to receive multi-vitamins or placebo, 1 tablet daily. The primary outcome event is the composite event "stroke, myocardial infarction, or death from any vascular cause", whichever occurs first. Our target is to recruit a total of 8,000 patients over the next two years with a median follow-up of 2.5 years. Recruitment to the trial began in November 1998 and is planned to continue until December 2005. We aim to complete final follow-up by the end of 2006. However, the Steering Committee will be flexible in dictating the need for ongoing recruitment and continuing follow-up, depending on the overall rate of the primary outcome event in the entire cohort at each interim analysis.


Options:
A: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2
C: Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet
D: Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A

Answer: C